| PANGAEA BIOTECH, S.A. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110142961 | METHODS AND REAGENTS FOR PREDICTING CLINICAL OUTCOME AND CUSTOMIZING CHEMOTHERAPY IN LUNG CANCER PATIENTS - The invention relates to methods for the prediction of the clinical outcome of a patient suffering from cancer based on the relative expression levels of BRCA1 and RAP80 genes. The invention also relates to anticancer combination therapies comprising a platinum-based chemotherapeutic agent and an inhibitor of RAP80. | 06-16-2011 |
| 20110086355 | BRCA1 mRNA EXPRESSION LEVELS PREDICT SURVIVAL IN BREAST CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY - The invention relates to methods for predicting the clinical outcome of a patient which suffers from breast cancer based on the expression levels of BRCA1, wherein low BRCA1 expression levels are indicative of a good prognosis. Moreover, the invention relates to methods for predicting the response to a neoadjuvant therapy based on a combination of an anti-metabolite, an intercalating agent and an alkylating agent of a patient which suffers from breast cancer based on the expression levels of BRCA1. | 04-14-2011 |
| 20100286187 | METHOD OF PREDICTING SURVIVAL OF A NON-SMALL-CELL LUNG CANCER PATIENT TO A CHEMOTHERAPEUTIC TREATMENT - Method for predicting the survival of a patient suffering from NSCLC to an antimicrotubule agent based chemotherapy treatment which comprises the step of determining the methylation state of a nucleic acid encoding CHFR in a biological sample from the patient, wherein the presence of methylation is indicative of longer survival of said patient as a response to said chemotherapy treatment. The methylation status of the CHFR gene can be easily determined in a serum sample. | 11-11-2010 |
| 20100167296 | METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIME AND SURVIVAL EXPECTANCY FOR NON SMALL CELL LUNG CANCER BASED ON EGFR/CSF-1/CA IX EXPRESSION - The present invention relates to a screening method for classifying and for deciding to apply chemotherapy to patients suffering from non-small-cell lung cancer (NSCLC), based on detecting the levels of EGFR, CSF-1 and CA IX. | 07-01-2010 |
| 20100009360 | METHOD FOR THE DETECTION OF EGFR MUTATIONS IN BLOOD SAMPLES - The present invention refers to the detection of EGFR mutations in a blood (serum/plasma) sample from a subject. The method comprises: (i) obtaining the DNA from said sample; (ii) amplifying the nucleic acid sequence corresponding to a specific region of the EGFR gene by means of PCR using a Protein-Nucleic Acid probe; 10 and (iii) detecting said mutation. | 01-14-2010 |
| 20090264641 | METHOD FOR THE ISOLATION OF MRNA FROM FORMALIN FIXED, PARAFFIN-EMBEDDED TISSUE - The invention provides a reliable method for recovering RNA from a formalin-fixed, paraffin-embedded biological tissue sample comprising:
| 10-22-2009 |
| 20090068657 | METHOD OF PREDICTING THE CLINICAL RESPONSE TO CISPLATIN OR CARBOPLATIN CHEMOTHERAPEUTIC TREATMENT - Method for predicting the survival of a patient suffering from NSCLC to a cisplatin or carboplatin based chemotherapy treatment which comprises the step of determining the methylation state of a nucleic acid encoding 14-3-3 sigma in a biological sample from the patient, wherein the presence of methylation is indicative of longer survival of said patient as a response to said chemotherapy treatment. The methylation status of the 14-3-3 sigma gene can be easily determined in a serum sample. | 03-12-2009 |
